Successful Use of Tofacitinib in Refractory Takayasu Arteritis: A Case Series.

Mediterr J Rheumatol · 2023 · PMC10628870 · PMID 37941853

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

9 Only two randomized controlled trials for the use of bDMARDs in TAK have been conducted to date, where abatacept (CTLA-4 antagonist) failed to show significant time in reduction to relapses 10 ; however, tocilizumab was promising as it showed a trend towards reduction in the time to relapse. 11 The superiority of biologicals over traditional DMARDs in TAK, however, has not yet been supported by high-quality evidence.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.